Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 104.99M shares rose 7.8% year over year, ahead of the +6.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.8% holds above the trailing-twelve-month pace of +6.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
104.99M+0.2% QoQ
Last fiscal yearDec 2025
104.79M+10.2% YoY
LTMMar 2026
102.01M+6.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.8%——
1 year+10.2%——
3-year CAGR+6.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
104.79M USD
Year-over-year change
+10.2%
4-year CAGR
+6.6%

Weighted Avg Shares vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 weighted avg shares of 102.01M shares is the 6th highest of the 11 companies compared; the peer median is 104.24M shares.
  • Its year-over-year change of +6.4% is the 7th highest of 11, against a peer median of +15.5%.
  • Over three fiscal years its annual growth of +6.2% compares with a peer median of +17.9%.
SRPT Competitors Peer median
Weighted Avg Shares for SRPT and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +21.7%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026132.45M +2.6%+2.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026102.01M +6.4%+6.2%
SLDBSolid Biosciences Inc.LTM Mar 202698.27M +94.3%+117.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
Peer median (excluding SRPT) 104.24M+15.5%+17.9%

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.